[go: up one dir, main page]

WO2002018620A3 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant Download PDF

Info

Publication number
WO2002018620A3
WO2002018620A3 PCT/US2001/025549 US0125549W WO0218620A3 WO 2002018620 A3 WO2002018620 A3 WO 2002018620A3 US 0125549 W US0125549 W US 0125549W WO 0218620 A3 WO0218620 A3 WO 0218620A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutrokine
alpha
methods
alphasv
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025549
Other languages
French (fr)
Other versions
WO2002018620A2 (en
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU2001288260A priority Critical patent/AU2001288260A1/en
Priority to CA002419661A priority patent/CA2419661A1/en
Priority to EP01967981A priority patent/EP1309718A4/en
Publication of WO2002018620A2 publication Critical patent/WO2002018620A2/en
Anticipated expiration legal-status Critical
Publication of WO2002018620A3 publication Critical patent/WO2002018620A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)

Abstract

The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
PCT/US2001/025549 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant Ceased WO2002018620A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001288260A AU2001288260A1 (en) 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant
CA002419661A CA2419661A1 (en) 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant
EP01967981A EP1309718A4 (en) 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US22562800P 2000-08-15 2000-08-15
US60/225,628 2000-08-15
US22700800P 2000-08-23 2000-08-23
US60/227,008 2000-08-23
US23433800P 2000-09-22 2000-09-22
US60/234,338 2000-09-22
US24080600P 2000-10-17 2000-10-17
US60/240,806 2000-10-17
US25002000P 2000-11-30 2000-11-30
US60/250,020 2000-11-30
US27624801P 2001-03-16 2001-03-16
US60/276,248 2001-03-16
US29349901P 2001-05-25 2001-05-25
US60/293,499 2001-05-25
US29612201P 2001-06-07 2001-06-07
US60/296,122 2001-06-07
US30480901P 2001-07-13 2001-07-13
US60/304,809 2001-07-13

Publications (2)

Publication Number Publication Date
WO2002018620A2 WO2002018620A2 (en) 2002-03-07
WO2002018620A3 true WO2002018620A3 (en) 2003-03-20

Family

ID=27578713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025549 Ceased WO2002018620A2 (en) 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant

Country Status (4)

Country Link
EP (1) EP1309718A4 (en)
AU (1) AU2001288260A1 (en)
CA (1) CA2419661A1 (en)
WO (1) WO2002018620A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
DK1415659T3 (en) 1999-01-25 2011-10-03 Biogen Idec Inc BAFF, inhibitors and its use in modulating B cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EA004635B1 (en) 1999-08-17 2004-06-24 Байоджен, Инк. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609583T3 (en) 2000-06-16 2017-04-21 Human Genome Sciences, Inc. Antibodies that bind immunospecifically to BLyS
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
AU2002351495A1 (en) * 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
EP1606312A2 (en) * 2003-03-07 2005-12-21 Xencor Inc. Baff mutants with at least one amino acid substitution and methods of their production
EP1608730B1 (en) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Truncated baff receptors
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
PL1631313T3 (en) 2003-06-05 2015-08-31 Genentech Inc Combination therapy for b cell disorders
EP2332563A3 (en) * 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731553B2 (en) * 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
EA200000311A1 (en) * 1997-09-12 2000-10-30 Апотек Р Энд Д Са NEW PROTEIN IMMUNE SYSTEM - KAU

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1309718A4 *

Also Published As

Publication number Publication date
EP1309718A2 (en) 2003-05-14
AU2001288260A1 (en) 2002-03-13
EP1309718A4 (en) 2004-08-25
CA2419661A1 (en) 2002-03-07
WO2002018620A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001055367A8 (en) Nucleic acids, proteins, and antibodies
WO2000032221A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2001055317A3 (en) Nucleic acids, proteins, and antibodies
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2005111072A3 (en) Notch-based fusion proteins and uses thereof
CY1109518T1 (en) Susceptor Activator of Growth Factors
WO2000053757A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO1998011234A3 (en) Human protein kinases
WO2002026781A3 (en) Ige receptor antagonists
WO2001025433A3 (en) Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
WO2001040464A8 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
AU5441200A (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2001055300A8 (en) Nucleic acids, proteins, and antibodies
WO2001055313A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2419661

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001967981

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001967981

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001967981

Country of ref document: EP